36976489|t|Effect of Nrf2 loss on senescence and cognition of tau-based P301S mice.
36976489|a|Cellular senescence may contribute to chronic inflammation involved in the progression of age-related diseases such as Alzheimer's disease (AD), and its removal prevents cognitive impairment in a model of tauopathy. Nrf2, the major transcription factor for damage response pathways and regulators of inflammation, declines with age. Our previous work showed that silencing Nrf2 gives rise to premature senescence in cells and mice. Others have shown that Nrf2 ablation can exacerbate cognitive phenotypes of some AD models. In this study, we aimed to understand the relationship between Nrf2 elimination, senescence, and cognitive impairment in AD, by generating a mouse model expressing a mutant human tau transgene in an Nrf2 knockout (Nrf2KO) background. We assessed senescent cell burden and cognitive decline of P301S mice in the presence and absence of Nrf2. Lastly, we administered 4.5-month-long treatments with two senotherapeutic drugs to analyze their potential to prevent senescent cell burden and cognitive decline: the senolytic drugs dasatinib and quercetin (DQ) and the senomorphic drug rapamycin. Nrf2 loss accelerated the onset of hind-limb paralysis in P301S mice. At 8.5 months of age, P301S mice did not exhibit memory deficits, while P301S mice without Nrf2 were significantly impaired. However, markers of senescence were not elevated by Nrf2 ablation in any of tissues that we examined. Neither drug treatment improved cognitive performance, nor did it reduce expression of senescence markers in brains of P301S mice. Contrarily, rapamycin treatment at the doses used delayed spatial learning and led to a modest decrease in spatial memory. Taken together, our data suggests that the emergence of senescence may be causally associated with onset of cognitive decline in the P301S model, indicate that Nrf2 protects brain function in a model of AD through mechanisms that may include, but do not require the inhibition of senescence, and suggest possible limitations for DQ and rapamycin as therapies for AD.
36976489	10	14	Nrf2	Gene	18024
36976489	51	54	tau	Gene	4137
36976489	61	66	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	67	71	mice	Species	10090
36976489	119	131	inflammation	Disease	MESH:D007249
36976489	163	183	age-related diseases	Disease	MESH:D010024
36976489	192	211	Alzheimer's disease	Disease	MESH:D000544
36976489	213	215	AD	Disease	MESH:D000544
36976489	243	263	cognitive impairment	Disease	MESH:D003072
36976489	278	287	tauopathy	Disease	MESH:D024801
36976489	289	293	Nrf2	Gene	18024
36976489	373	385	inflammation	Disease	MESH:D007249
36976489	446	450	Nrf2	Gene	18024
36976489	499	503	mice	Species	10090
36976489	528	532	Nrf2	Gene	18024
36976489	586	588	AD	Disease	MESH:D000544
36976489	660	664	Nrf2	Gene	18024
36976489	694	714	cognitive impairment	Disease	MESH:D003072
36976489	718	720	AD	Disease	MESH:D000544
36976489	738	743	mouse	Species	10090
36976489	770	775	human	Species	9606
36976489	776	779	tau	Gene	4137
36976489	796	800	Nrf2	Gene	18024
36976489	869	886	cognitive decline	Disease	MESH:D003072
36976489	890	895	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	896	900	mice	Species	10090
36976489	932	936	Nrf2	Gene	18024
36976489	1083	1100	cognitive decline	Disease	MESH:D003072
36976489	1122	1131	dasatinib	Chemical	MESH:D000069439
36976489	1136	1145	quercetin	Chemical	MESH:D011794
36976489	1147	1149	DQ	Chemical	-
36976489	1176	1185	rapamycin	Chemical	MESH:D020123
36976489	1187	1191	Nrf2	Gene	18024
36976489	1232	1241	paralysis	Disease	MESH:D010243
36976489	1245	1250	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	1251	1255	mice	Species	10090
36976489	1279	1284	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	1285	1289	mice	Species	10090
36976489	1306	1321	memory deficits	Disease	MESH:D008569
36976489	1329	1334	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	1335	1339	mice	Species	10090
36976489	1348	1352	Nrf2	Gene	18024
36976489	1434	1438	Nrf2	Gene	18024
36976489	1603	1608	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	1609	1613	mice	Species	10090
36976489	1627	1636	rapamycin	Chemical	MESH:D020123
36976489	1846	1863	cognitive decline	Disease	MESH:D003072
36976489	1871	1876	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;CorrespondingGene:4137;RS#:63751438;CorrespondingSpecies:9606;CA#:225439
36976489	1898	1902	Nrf2	Gene	18024
36976489	1941	1943	AD	Disease	MESH:D000544
36976489	2067	2069	DQ	Chemical	-
36976489	2074	2083	rapamycin	Chemical	MESH:D020123
36976489	2101	2103	AD	Disease	MESH:D000544
36976489	Association	MESH:D003072	RS#:63751438;HGVS:p.P301S;CorrespondingGene:4137
36976489	Association	MESH:D008569	18024
36976489	Association	MESH:D007249	18024
36976489	Negative_Correlation	MESH:D000069439	MESH:D003072
36976489	Association	MESH:D010243	18024
36976489	Negative_Correlation	MESH:D011794	MESH:D003072
36976489	Association	MESH:D000544	18024
36976489	Association	MESH:D003072	18024
36976489	Negative_Correlation	MESH:D020123	MESH:D000544
36976489	Association	18024	4137
36976489	Negative_Correlation	MESH:D020123	MESH:D003072
36976489	Association	MESH:D000069439	18024
36976489	Association	MESH:D003072	4137

